MannKind | MNKD - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Adma Biologics USD 50.29M 12.46M 2026-03
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Insmed USD -101.31M 98.97M 2026-06
Karyopharm Therapeutics USD -26.76M 8.92M 2026-03
MacroGenics USD -33.44M 21.34M 2026-03
MannKind USD -68.23M 8.76M 2026-06
Merck USD 840M 2.72B 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Novavax USD 20.94M 100.32M 2025-12
Novo Nordisk DKK 5.25B 54.37B 2026-06
Pfizer USD 667M 4.32B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Xencor USD -36.6M 41.26M 2026-06